Deferring systemic therapy may improve survival outcomes in carefully selected patients with metastatic renal cell carcinoma, new data suggest.
Hepatocellular carcinoma (HCC) management is rapidly evolving as systemic therapies and locoregional treatments are increasingly combined across disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results